PubMed Health⌕ Search

PubMed · 10986542

Sample size calculations with compliance information.

Abstract

In randomized clinical trials, non-compliance will lead to the loss of power in the standard intention-to-treat analysis and one should account for this in sample size calculations. In this paper a new sample size formula for a binary outcome is proposed in which compliance information is considered. The proposed method is based purely on the treatment randomization. We compare it to the conventional sample size calculation method based on the two independent binomial distributions assumption. We examine 3100 combinations of risks of control group (baseline risks), treatment effects (risk differences), compliances in the test treatment group and the control treatment group, test sizes and powers. We found that, compared to the conventional method, the proposed method gives similar sample sizes for baseline risks 0.4-0.6, larger sample sizes for baseline risks less than 0.4, and smaller sample sizes for baseline risks greater than 0.6 when the true risk difference is negative.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Sato. 2000-10-15. Sample size calculations with compliance information.. https://doi.org/10.1002/1097-0258(20001015)19%3A19%3C2689%3A%3Aaid-sim555%3E3.0.co%3B2-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗